Martin J Edelman MD

PubMed

• Resistance to Immune Checkpoint Inhibitor Treatment in Non-Small Cell Lung Cancer Clinical Trials: A Perspective From Lung-MAP Investigators.
  Deborah B Doroshow, Ticiana A Leal, Saiama N Waqar, Hossein Borghaei, D Ross Camidge
  Journal of Clinical Oncology. 2026-10-01
• Safety and Biomarker Analysis of NRG-LU004: Phase I Trial of Accelerated or Conventionally Fractionated Radiation Therapy Combined With Durvalumab in Programmed Death ...
  Steven H Lin, Stephanie L Pugh, Diane Marie Del Valle, Vladimir Roudko, Martin J Edelman
  International Journal of Radiation Oncology, Biology, Physics. 2026-09-12
• Executive Summary of the American Radium Society Appropriate Use Criteria for a Multidisciplinary Treatment Approach to the Management of Resectable Esophageal and Gas...
  Christopher J Anker, Aditya Juloori, D Chamil Codipilly, Percy Lee, Krishan R Jethwa
  International Journal of Radiation Oncology, Biology, Physics. 2026-08-25

Journal Articles

• Lymph Node Size Predicts for Asymptomatic Brain Metastases in Non-Small Cell Lung Cancer Patients at Diagnosis  
  Martin J Edelman, Josephine Feliciano, Clinical Lung Cancer
• Chemotherapy dose reduction due to chemotherapy induced peripheral neuropathy in breast cancer patients receiving chemotherapy in the neoadjuvant or adjuvant settings:...  
  Bhatnagar  B, Gilmore  S, Goloubeva  O, Pelser  C, Medeiros  M, Chumsri  S, Tkaczuk  K, Edelman M, Bao  T, SpringerPlus, 1/1/2014
• RTOG 02-29: A Phase II Trial of Neoadjuvant Therapy with Concurrent Chemotherapy and Full Dose Radiotherapy Followed by Surgical Resection and Consolidative Therapy fo...  
  Suntharalingam M, Paulus R, Edelman MJ, Krasna M, Burrows W, Gore E, Yom S, Choy H, International Journal of Radiation Oncology, Biology, Physics, 10/1/2012

Books/Book Chapters

• Am Soc Clin Oncol Educ Book 
  Chapter: 50 Years of progress in the systemic therapy of non-small cell lung cancer. 
  Wakelee H, Kelly K, Edelman MJ2014
• Advances in Radiation Oncology in Lung Cancer 
  Chapter: "Novel Targeted Agents and Radiopharmaceuticals in Lung Cancer" 
  Page 773 - 792Edelman MJ, Ijaz NEditors: B Jeremic.Springer-Verlag2011
• Encyclopedia of Respiratory Medicine 
  Chapter: "Chemotherapeutic Agents" 
  Page 332 - 339Edelman MJ and RupardEEditors: GJ Laurent and SD Shapiro.Elsevier Ltd.2006

Abstracts/Posters

• Phase III randomized, placebo controlled trial of COX-2 inhibition in addition to standard chemotherapy for advanced non-small cell lung cancer (NSCLC):CALGB 30801 (Al...
  Edelman MJ, Wang X-F,Hodgson L, Cheney RT, Baggstrom M, Sachdev T, Gajra A, Bertino E, Reckamp K, Molina J, Schiller J, Mitchell-Richards K, Friedman P, Ritter J, Vokes E, Proceedings AACR, 1/1/2014
• A Phase I Dose Escalation Trial of MAGE-A3 and HPV-16 Specific Peptide Immunomodulatory Vaccines in Patients with Recurrent/Metastatic Squamous Cell Carcinoma of the H...
  Zandberg D, Rollins S, Morales R, Taylor R, Wolf J, Cullen K, Ord R, Lubeck F, Papadimetriou JC, Mann D, Strome S, Edelman MJ, Proceedings ASCO, 1/1/2014
• Onartuzumab + erlotinib versus erlotinib in previously treated Stage IIIb or IV NSCLC: results from the pivotal Phase III randomized multi-center, placebo controlled M...
  Spigel DR, Edelman MJ, O'Byrne K, Paz-Ares L, Shames DS, Yu W, Paton VE, Mok TS, Proceedings ASCO, 1/1/2014

Lectures

• A two-part, open-label, randomized, phase 2/3 study of dinutuximab and irinotecan versus irinotecan for second-line treatment of subjects with relapsed or refractory s... 
  2018 ASCO Annual Meeting - Chicago, Illinois - 06/3/2018
• "Targeted Therapies in Lung Cancer" 
  Gdansk, Poland - 8/30/2014
• Internal Medicine Grand Rounds: "Current Status of Treatment of Non-small Cell Lung Cancer." 
  University of New Mexico, Albuquerque, NM - 1/16/2014

Other

• Lung Cancer Case Studies. 
  Gandara DR, Edelman MJ, Marelich G
  http://www.vlh.com
• Integration of New Chemotherapeutic Agents Into Combined Modality Therapy of Stage III Non-Small Cell Lung Cancer. 
  Gandara DR, Edelman MJ, Lau D, Roach M, Proc Current Approaches Rad Oncol, Biol, Physics
  1/1/1995
• Promising New Agents in the Treatment of Lung Cancer: Potential for Combined Modality Therapy. 
  Gandara DR, Edelman MJ, Proc Current Approaches Rad Oncol, Biol, Physics
  1/1/1993